189_ MMJ Holdings Moves Ahead with FDA Approved Botanical Drug Pathway

Today, we're joined by Duane Boise, CEO of MMJ Holdings, a biopharmaceutical company advancing cannabis-derived medicines through the FDA's botanical Drug Development Pathway. MMJ has received Orphan drug designation for Huntington's disease and multiple sclerosis, and its cannabis-derived soft-gel formulations are now preparing to enter phase 2 clinical trials, helping pave the way for a new era of FDA-validated cannabis medicine.  Duane shares the long road to reaching this milestone, the challenges of bringing cannabis-based therapeutics through the FDA process, and what the future may hold for cannabis as a mainstream medicine.  https://mmjih.com  https://www.linkedin.com/in/duane-boise-b174b9168/ The Innovating Cannabis podcast is produced and hosted by Pam Chmiel, a freelance writer and editor for the Cannabis Industry Journal. Get in touch with [email protected]   Twitter   InstagramPlease like the show to help us reach more listeners🙏🏻  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.